Solera says its curated digital health network can reduce total health plan claims by 2%–4%

Solera puts total plan savings claim on the table

Solera Health operates a curated network of digital health programs. Its March 2026 white paper makes a consequential purchaser claim: results from members enrolled through the Solera network could translate into a 2%–4% reduction in total health-plan claims costs.

The estimate begins with a retrospective 6-month claims analysis involving 16,499 Solera enrollees and 34,892 matched controls. Solera reports that enrolled members had $1,241 lower med/Rx spending, generated a $2.42 ROI, and experienced fewer emergency department visits and hospitalizations.

Those findings warrant examination.

The underlying study provides conditional support

Solera describes a plausible observational study design. Controls were members already receiving conventional care for similar conditions rather than untreated individuals. The analysis reportedly used temporal matching, baseline spending, propensity-score matching across more than 50 variables, comorbidity adjustment, and doubly robust estimation.

But the public record contains only a summary of that work. The white paper cites a separate Technical Study Report and an independent actuarial validation memorandum. Neither is available in the public materials reviewed here.

The reported findings are therefore conditionally established in the public record: Solera describes a credible study architecture and reports findings consistent with the proposed economic mechanism, but the materials needed to independently assess the analysis in sufficient detail are unavailable.

That is more informative than an unsupported savings assertion. It is not the same as a fully inspectable evidentiary result.

The 2%–4% result requires the evidence to travel farther

The study did not measure a 2%–4% reduction in total plan claims.

Solera observed enrolled members for six months and reported a $1,241 difference in medical and pharmacy spending. It then illustrates what that result could mean for a 100,000-member health plan.

The calculation assumes annual claims of $6,500 per member, or $650 million for the plan. The six-month $1,241 result is doubled to create an annualized figure. Solera then applies that result to 5,000 and 10,000 participating members, producing approximately $12.4 million and $24.8 million in savings—roughly 2% and 4% of the illustrative plan’s claims.

The arithmetic is clear. The assumptions require further support.

First, six months of reported results become twelve months of assumed results. Solera itself identifies longer-term persistence as unresolved and describes 12- and 24-month analyses as future work.

Second, the population pathway needs reconciliation. The paper describes 5% and 10% enrollment “among eligible members,” but the calculation uses 5,000 and 10,000 participants in a 100,000-member plan—5% and 10% of total membership. Unless the full plan population is eligible, those are not equivalent assumptions.

A purchaser therefore needs to reconstruct:

Covered Population → Clinically Eligible Population → Identified Members → Enrollment → Sustained Participation → Reported Participant Effect → Total Plan Effect

The study reports the participant effect. It does not establish the full pathway required to generate the plan-level percentage.

The network and the programs inside it are different analytical objects

Solera’s proposition is broader than access to individual digital health programs. It argues that curation, matching, integration, and performance-based payment create a more effective digital health network.

For that model to create purchaser savings, Solera must identify and match an appropriate member, the underlying intervention must change care or behavior, utilization must change, claims must decline, and the resulting economic value must exceed the complete cost of the intervention and network.

The reported analysis appears to compare members enrolled through Solera with matched members receiving conventional care. That can provide evidence about the combined model delivered through Solera.

What should a purchaser ask?

Before underwriting a material reduction in plan claims, a purchaser should ask:

• Can we review the complete technical study and independent actuarial validation materials?

• What percentage of our covered population is eligible for the programs represented in the study?

• What enrollment and sustained participation rates are required within that eligible population to reproduce the modeled plan-level effect?

• What evidence identifies the incremental value of Solera’s curation and matching functions rather than the value of the underlying interventions?

What the evidence permits today

Solera has presented more than a bare savings assertion. It reports results from a reasonably constructed observational analysis and provides enough methodological description to make the findings worth further examination.

But the public evidentiary record supports only conditional reliance on those findings, and the 2%–4% whole-plan proposition requires additional assumptions that were not demonstrated by the study.

For a purchaser, the 2%–4% figure is best treated as an underwriting scenario to test against its own eligibility, enrollment, persistence, program mix, claims base, and complete solution costs—not as an established plan-level savings result.